Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29896141 | 1.00 | SCN2A (0.51) | SCN2ASCN10AMAPK8PIK3CALMNA | |
| SCHEMBL29896163 | 0.91 | CDK2 (0.48) | SCN2ASCN10AMAPK8PIK3CAKDM4E | |
| SCHEMBL27188821 | 0.91 | CDK2 (0.48) | SCN2ASCN10AMAPK8PIK3CAKDM4E | |
| SCHEMBL27188828 | 0.87 | PIK3CA (0.46) | SCN2ASCN10AMAPK8PIK3CALMNA | |
| SCHEMBL29896135 | 0.87 | PIK3CA (0.46) | SCN2ASCN10AMAPK8PIK3CALMNA | |
| SCHEMBL29896176 | 0.86 | PIK3CA (0.42) | SCN2ASCN10AMAPK8PIK3CAKDM4E | |
| SCHEMBL27188849 | 0.86 | PIK3CA (0.42) | SCN2ASCN10AMAPK8PIK3CAKDM4E | |
| SCHEMBL29896150 | 0.81 | DDR1 (0.48) | SCN2ASCN10APIK3CAKDM4EROCK2 | |
| SCHEMBL29896090 | 0.81 | SCN2A (0.46) | SCN2ASCN10AMAPK8LMNAMAPK1 | |
| SCHEMBL27188824 | 0.81 | SCN2A (0.46) | SCN2ASCN10AMAPK8LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | claimed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | SCN2A 31/4885SCN10A 29/4885MAPK8 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.